News
CNTB
2.390
+0.42%
0.010
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON), Alnylam Pharma (ALNY) and Connect Biopharma Holdings (CNTB)
TipRanks · 1d ago
Weekly Report: what happened at CNTB last week (0622-0626)?
Weekly Report · 2d ago
Connect Biopharma Price Target Announced at $7.00/Share by Piper Sandler
Dow Jones · 5d ago
Piper Sandler Initiates Coverage On Connect Biopharma Hldgs with Overweight Rating, Announces Price Target of $7
Benzinga · 5d ago
Biren Amin Initiates Buy on Rademikibart Developer with Overweight Rating and DCF-Based $7 Price Target on Differentiated Asthma/COPD Opportunity
TipRanks · 5d ago
Connect Biopharma initiated with an Overweight at Piper Sandler
TipRanks · 5d ago
CONNECT BIOPHARMA HOLDINGS LTD <CNTB.O>: PIPER SANDLER INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $7
Reuters · 5d ago
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
Benzinga · 6d ago
Connect Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 6d ago
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
TipRanks · 06/22 10:48
Weekly Report: what happened at CNTB last week (0615-0619)?
Weekly Report · 06/22 10:39
Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Tyra Bioscience (TYRA)
TipRanks · 06/18 12:50
Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Alkermes (ALKS) and Connect Biopharma Holdings (CNTB)
TipRanks · 06/18 10:51
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM) and Connect Biopharma Holdings (CNTB)
TipRanks · 06/17 17:50
Connect Biopharma Completes Enrollment In Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart As Adjunct To Standard Of Care For Acute Exacerbations In Asthma And Type 2 Inflammation
Benzinga · 06/17 13:02
Connect Biopharma completes Phase 2 Seabreeze STAT asthma trial enrollment for rademikibart
PUBT · 06/17 13:01
CONNECT BIOPHARMA ANNOUNCES COMPLETION OF ENROLLMENT OF PHASE 2 SEABREEZE STAT ASTHMA STUDY EVALUATING RADEMIKIBART FOR THE TREATMENT OF ACUTE EXACERBATIONS IN ASTHMA
Reuters · 06/17 13:00
CONNECT BIOPHARMA - TO REPORT TOPLINE DATA FROM SEABREEZE STAT ASTHMA STUDY IN EARLY SEPTEMBER 2026
Reuters · 06/17 13:00
Weekly Report: what happened at CNTB last week (0608-0612)?
Weekly Report · 06/15 10:39
Weekly Report: what happened at CNTB last week (0601-0605)?
Weekly Report · 06/08 10:34
More
Webull provides a variety of real-time CNTB stock news. You can receive the latest news about Connect Biopharma Holdings Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CNTB
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.